for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bellerophon Therapeutics Inc

BLPH.OQ

Latest Trade

0.39USD

Change

0.02(+5.46%)

Volume

51,192

Today's Range

0.37

 - 

0.39

52 Week Range

0.34

 - 

1.22

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Bellerophon Presents New Data From Cohort 1 Of Ongoing Phase 2/3 Study Of Inopulse

Nov 7 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON PRESENTS NEW DATA FROM COHORT 1 OF ONGOING PHASE 2/3 STUDY OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AT PULMONARY FIBROSIS FOUNDATION SUMMIT 2019.BELLEROPHON THERAPEUTICS INC - INOPULSE DEMONSTRATED A CONSISTENT AND CLINICALLY MEANINGFUL BENEFIT IN MODERATE TO VIGOROUS PHYSICAL ACTIVITY.

Bellerophon Provides Business Update And Reports Third Quarter 2019 Financial Results

Nov 6 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.06.Q3 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.ANTICIPATE INITIATING PIVOTAL COHORT DURING THE FIRST QUARTER OF 2020.BELLEROPHON THERAPEUTICS- AS OF SEPT 30, CO HAD CASH AND CASH EQUIVALENTS OF $12.8 MILLION, COMPARED TO $16.6 MILLION AT DEC 31, 2018.

Bellerophon Reports Q2 Loss Per Share $0.06

Aug 8 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.06.AS OF JUNE 30, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $16.8 MILLION, COMPARED TO $16.6 MILLION AT DECEMBER 31, 2018.Q2 EARNINGS PER SHARE VIEW $-0.07 -- REFINITIV IBES DATA.

Bellerophon Says FDA Agreed With Proposed Primary Endpoint

Aug 1 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON THERAPEUTICS INC - TOP-LINE DATA FROM COHORT 1 SHOWED THAT INOPULSE DEMONSTRATED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT.BELLEROPHON THERAPEUTICS INC - U.S. FOOD AND DRUG ADMINISTRATION AGREED WITH BELLEROPHON'S PROPOSAL THAT MVPA SERVE AS PRIMARY ENDPOINT.BELLEROPHON THERAPEUTICS INC - FDA ALSO AGREED WITH BELLEROPHON'S PROPOSAL THAT INO-PF BE AMENDED FROM A PHASE 2B STUDY TO A PHASE 2/3 TRIAL.

Bellerophon To Present Additional Data From Cohort 1 Of Ongoing Phase 2/3 Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease

May 13 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON TO PRESENT ADDITIONAL DATA FROM COHORT 1 OF ONGOING PHASE 2/3 STUDY OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AT AMERICAN THORACIC SOCIETY 115TH INTERNATIONAL CONFERENCE.BELLEROPHON THERAPEUTICS INC - RESULTS TO BE PRESENTED IN LATE-BREAKING ABSTRACT AS AN ORAL PRESENTATION.BELLEROPHON THERAPEUTICS INC - COMPANY WILL ALSO PRESENT A CORPORATE OVERVIEW AND UPDATE ON ITS PH-ILD PROGRAM AT RESPIRATORY INNOVATION SUMMIT.BELLEROPHON THERAPEUTICS INC - OVERALL ACTIVITY IMPROVED BY 12% (0% CHANGE ON INO VERSUS. 12% DECREASE ON PLACEBO; P=0.05).BELLEROPHON THERAPEUTICS INC - NT-PROBNP IMPROVED BY 27% (15% INCREASE ON INO VERSUS. 42% INCREASE ON PLACEBO).BELLEROPHON THERAPEUTICS INC - BELLEROPHON ALSO EXPECTS TO INITIATE COHORT 3 IN SECOND HALF OF 2019.

Bellerophon Therapeutics Q1 Loss Per Share $0.01

May 9 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.01.AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $20.7 MILLION, COMPARED TO $16.6 MILLION AT DECEMBER 31, 2018.

Bellerophon Therapeutics Reports Q4 Loss Per Share Of $0.02

March 14 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $16.6 MILLION.

Bellerophon Therapeutics - Public Offering Of 10 Million Common Shares Priced At $0.70 Per Share

Jan 23 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON ANNOUNCES PRICING OF $7 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $0.70PER SHARE.

Bellerophon Therapeutics Inc Announces Proposed Public Offering Of Common Stock

Jan 22 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BELLEROPHON THERAPEUTICS INC - BELLEROPHON INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO FUND WORKING CAPITAL.

Bellerophon Announces Top-Line Results From Cohort 1 Of Inopulse Phase 2B Clinical Trial

Jan 7 (Reuters) - Bellerophon Therapeutics Inc <BLPH.O>::BELLEROPHON ANNOUNCES TOP-LINE RESULTS FROM COHORT 1 OF THE INOPULSE® PHASE 2B CLINICAL TRIAL FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE.BELLEROPHON THERAPEUTICS INC - INO WAS WELL-TOLERATED WITH NO SAFETY CONCERNS.BELLEROPHON THERAPEUTICS - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MULTIPLE CLINICALLY MEANINGFUL ACTIVITY PARAMETERS WERE OBSERVED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up